Piermont Capital Management’s Anika Therapeutics ANIK Stock Holding History

Piermont Capital Management’s Portfolio ANIK Stock Details ANIK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	$1.34M	Buy	39,950 +800	+2%	+$28.9K	0.64%	84
2018 Q3	$1.65M	Sell	39,150 -5,974	-13%	-$236K	0.66%	87
2018 Q2	$1.44M	Buy	45,124 +1,800	+4%	+$74.1K	0.44%	104
2018 Q1	$2.15M	Buy	43,324 +5,040	+13%	+$285K	0.72%	52
2017 Q4	$2.06M	Sell	38,284 -1,540	-4%	-$85.2K	0.68%	67
2017 Q3	$2.31M	Hold	39,824	–	–	0.76%	52
2017 Q2	$1.97M	Sell	39,824 -10,176	-20%	-$469K	0.56%	65
2017 Q1	$2.17M	Sell	50,000 -3,535	-7%	-$169K	0.52%	81
2016 Q4	$2.62M	Sell	53,535 -3,604	-6%	-$167K	0.6%	65
2016 Q3	$2.73M	Sell	57,139 -23,349	-29%	-$1.15M	0.65%	58
2016 Q2	$4.32M	Buy	80,488 +66,788	+488%	+$3.15M	1.12%	2
2016 Q1	$613K	Sell	13,700 -300	-2%	-$12.2K	0.2%	126
2015 Q4	$534K	Sell	14,000 -1,240	-8%	-$47.4K	0.17%	134
2015 Q3	$485K	Hold	15,240	–	–	0.16%	134
2015 Q2	$503K	Sell	15,240 -500	-3%	-$17.8K	0.15%	167
2015 Q1	$648K	Buy	15,740 +5,360	+52%	+$217K	0.2%	126
2014 Q4	$423K	Sell	10,380 -140	-1%	-$5.47K	0.15%	114
2014 Q3	$386K	Buy	10,520 +4,690	+80%	+$203K	0.15%	114
2014 Q2	$270K	Hold	5,830	–	–	0.11%	109
2014 Q1	$240K	Hold	5,830	–	–	0.12%	111
2013 Q4	$222K	Buy	+5,830	New	+$180K	0.11%	112

Other funds holding ANIK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return

Engaged Capital Newport Beach, California $327M AUM 22.96% 1-Year Est. Return

AAM

AMI Asset Management Los Angeles, California $1.74B AUM 26.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Piermont Capital Management's ANIK Position: Q4 2018 in Review

Piermont Capital Management increased its Anika Therapeutics (ANIK) stake by 2% in Q4 2018, buying an estimated $28.9K and bringing the position to 39,950 shares worth $1.34M. The position accounts for 0.64% of the portfolio, ranked #84.

Piermont Capital Management first reported a position in ANIK in Q4 2013 and has held it in 21 quarters since. The position peaked at $4.32M in Q2 2016. 162 funds tracked by Wall St. Rank hold ANIK as of Q4 2018.

Piermont Capital Management held 39,950 shares of Anika Therapeutics worth $1.34M as of Q4 2018.
Piermont Capital Management bought 800 Anika Therapeutics shares in Q4 2018, an estimated $28.9K.
Anika Therapeutics made up 0.64% of Piermont Capital Management's portfolio in Q4 2018, its #84 holding.
Piermont Capital Management first reported a position in Anika Therapeutics in Q4 2013 and has held it in 21 quarters since.
Piermont Capital Management's Anika Therapeutics position peaked at $4.32M in Q2 2016.
162 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2018.

Based on Piermont Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.